We developed paclitaxome-2, an optimized version of the sphingomyelin-derived paclitaxel nanovesicle paclitaxome. Leveraging the cationization-enabled transcytosis machinery boosted tumor penetration, and incorporating CD47 ‘self’ peptide masking minimized phagocytosis. Co-delivery of gemcitabine or carboplatin improved therapeutic outcomes in advanced pancreatic cancer and post-surgical triple-negative breast cancer in mouse models.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Sofias, A. M., Dunne, M., Storm, G. & Allen, C. The battle of ‘nano’ paclitaxel. Adv. Drug Delivery Rev. 122, 20–30 (2017). This review covers PTX formulations.
Wang, Z. et al. Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy. Nat. Nanotechnol. 16, 1130–1140 (2021). This paper reports our pioneering SM-derived drug bilayer nanovesicles.
Luo, M. et al. A STING-activating nanovaccine for cancer immunotherapy. Nat. Nanotechnol. 12, 648–654 (2017). This paper reports the pH-sensitive probe used in the functionalization of paclitaxome.
Rodriguez, P. L. et al. Minimal ‘self’ peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 339, 971–975 (2013). This paper reports the CD47 ‘self’ peptide used in the functionalization of paclitaxome.
Meng, F. et al. A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces anti-tumor immunity. Proc. Natl Acad. Sci. USA 119, e2122595119 (2022). This paper reports use of the immunogenic cell death inducer paclitaxel together with nucleic acids for improved tumor elimination.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Wang, Z. et al. A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer. Nat. Cancer https://doi.org/10.1038/s43018-025-01029-7 (2025).
Rights and permissions
About this article
Cite this article
A sphingolipid-derived paclitaxel nanovesicle for improved cancer therapy. Nat Cancer 6, 1619–1620 (2025). https://doi.org/10.1038/s43018-025-01030-0
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s43018-025-01030-0
